Chronic Kidney Disease Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Department of Physiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Curr Med Chem. 2023;30(25):2850-2863. doi: 10.2174/0929867329666220831151645.
Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and morbidity worldwide. It leads to various long-term complications such as diabetic nephropathy. Diabetes nephropathy is the leading cause of renal failure in patients with chronic kidney diseases undergoing hemodialysis. Hence preventing the development and progression of diabetic nephropathy is one of the main goals in the management of patients with type 2 diabetes. Sodium-glucose cotransporter 2 inhibitors of empagliflozin is a potent anti-hyperglycemic agents. In addition, it has been shown to have some pharmacologic potentials to provide renoprotective effects in patients with T2DM. In the current study, we review the available clinical data on the potential renoprotective effects of this drug from a mechanistic and molecular viewpoint.
2 型糖尿病（T2DM）是全球主要的死亡和发病原因之一。它会导致各种长期并发症，如糖尿病肾病。糖尿病肾病是慢性肾脏病患者进行血液透析时导致肾衰竭的主要原因。因此，预防糖尿病肾病的发生和进展是 2 型糖尿病患者管理的主要目标之一。钠-葡萄糖共转运蛋白 2 抑制剂恩格列净是一种有效的降血糖药物。此外，研究表明，它在 T2DM 患者中具有一些药理潜力，可以提供肾脏保护作用。在本研究中，我们从机制和分子角度综述了该药物潜在肾脏保护作用的现有临床数据。
